Search Results - "Viansone, A."

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer by Viansone, A., Pellegrino, B., Omarini, C., Pistelli, M., Boggiani, D., Sikokis, A., Uliana, V., Zanoni, D., Tommasi, C., Bortesi, B., Bonatti, F., Piacentini, F., Cortesi, L., Camisa, R., Sgargi, P., Michiara, M., Musolino, A.

“…HER2-positive breast cancers are rare amongst BRCA mutation carriers. No data exist regarding clinicopathological characteristics and prognosis of this…”
Get full text

Optimizing the Management of Cancer Patients Treated With Systemic Therapies During the COVID-19 Pandemic: The New Role of PCR and CT Scan by Viansone, Alessandro A., Ammari, Samy, Dercle, Laurent, Arnedos, Monica

“…In late 2019 and early 2020, the world witnessed the outbreak of the SARS-CoV-2 (also referred as COVID-19) in Wuhan, China. Its rapid expansion worldwide and…”
Get full text

Feasibility and Safety of the “One-Week Breast Radiation Therapy” Program by Ba, M.B., Giudici, F., Bellini, C., Auzac, G., Louvel, G., Bockel, S., Moukasse, Y., Chaffai, I., Berthelot, K., Vatonne, A., Conversano, A., Viansone, A., Larue, C., Deutsch, E., Michiels, S., Milewski, C., Rivera, S.

“…FAST-Forward and UK-FAST-trials have demonstrated the safety and efficacy of five-fraction breast adjuvant radiation therapy (RT) and have become the standard…”
Get full text

Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series by Leonetti, Alessandro, D'Abbiero, Nunziata, Baldari, Giorgio, Andreani, Stefano, Ruffini, Livia, Viansone, Alessandro A, Buti, Sebastiano

“…Objectives To investigate the efficacy of stereotactic body radiotherapy in oligometastatic urothelial carcinoma with node‐only involvement. Methods We…”
Get full text

Feasibility and Safety of the u201cOne-Week Breast Radiation Therapyu201d Program by Ba, M. B., Bellini, C., Auzac, G., Louvel, G., Bockel, S., Moukasse, Y., Chaffai, I., Berthelot, K., Vatonne, A., Deutsch, E., Milewski, C., Rivera, S., Giudici, F., Larue, C., Michiels, S., Conversano, A., Viansone, A.

“…© 2024 The Royal College of RadiologistsAims: FAST-Forward and UK-FAST-trials have demonstrated the safety and efficacy of five-fraction breast adjuvant…”
Get full text

Incidence of adverse events in older patients treated with Chemotherapy+Immunotherapy combinations by Rached, L., Laparra, A., Aldea, M., Frelaut, M., Besse, B., Planchard, D., Viansone, A., Larive, A., Danlos, F.X., Goldschmidt, V., Beraud-Chaulet, G., Lazarovici-Nagera, C., Ap-Thomas, Z., Marabelle, A., Champiat, S., Mourato-Ribeiro, J., Even, C., Aix, S. Ponce, Baldini, C.

Get full text

Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial by Brain, Etienne, Viansone, Alessandro A., Bourbouloux, Emmanuelle, Rigal, Olivier, Ferrero, Jean-Marc, Kirscher, Sylvie, Allouache, Djelila, D'hondt, Veronique, Savoye, Aude Marie, Durando, Xavier, Duhoux, Francois P., Venat-Bouvet, Laurence, Blot, Emmanuel, Canon, Jean-Luc Re, Rollot, Florence, Bonnefoi, Herve R., Lemonnier, J., Lacroix-Triki, Magali, Bonnetain, Franck, Vernerey, Dewi

“…500 Background: Benefit of adjuvant chemotherapy (CT) in addition to endocrine therapy (ET) remains controversial for patients (pts) aged ≥ 70 years with…”
Get full text